FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Oxford Nanopore Technologies plc Stock AnalysisComprehensive stock analysis for Oxford Nanopore Technologies plc (ONTTF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisONTTF
ONTTF
Oxford Nanopore Technologies plc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ONTTF
Home🔹Stocks🔹Oxford Nanopore Technologies plc

Oxford Nanopore Technologies plc

🇺🇸ONTTF•OTC

Oxford Nanopore Technologies plc

🇺🇸ONTTF•OTC
Market cap
$1.79B
Sentiment

Your view on ONTTF

Mkt Cap
$1.79B
Sentiment
Your view
ONTTF
Oxford Nanopore Technologies plc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ONTTF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Oxford Nanopore Technologies plc

Industry
Biotechnology
Sector
Healthcare
CEO
Gurdial Singh Sanghera
Headquarters
Gosling Building, Oxford, GB
Industry
Biotechnology
Sector
Healthcare
CEO
Gurdial Singh Sanghera
Headquarters
Gosling Building, Oxford, GB
Description

Oxford Nanopore Technologies plc develops and commercializes a technology platform using nanopore-based sensing for the analysis of various types of molecules.

The company offers MinION, a portable device for deoxyribonucleic acid and ribonucleic acid sequencing; GridION, a self-contained benchtop device for running and analyzing up to five MinION or Flongle flow cells; MinION Mk1C for basecalling and data analysis, touchscreen operation, and wireless connectivity; Flongle, an adapter for use in MinION or GridION devices to attach a Flongle flow cell; GridION Mk1, a benchtop nanopore sequencer; PromethION 2 Solo and PromethION 2, a low-cost access to high-yield PromethION sequencing; PromethION 24 and PromethION 48 benchtop nanopore-based sequencers for multiple users to deliver multi-sample and multi-experiment sequencing results; and VolTRAX, an USB-powered device, which automates laboratory processes upstream of nanopore sequencing.

It also provides MinKNOW, a software that offers data acquisition, real-time analysis and feedback, local basecalling, and data streaming; Basecalling tools to determine the identity and order of bases on the DNA/RNA molecule; EPI2ME, a cloud-based data analysis platform for end-to-end analysis of nanopore data in real time; and EPI2ME Labs, a bioinformatics solution to assist users in developing their skills and confidence in the analysis of their nanopore-based sequencing data.

In addition, the company is developing MinION Mk1D; Ubi; Plongle; and SmidgION products. It sells its products online. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008.

Oxford Nanopore Technologies plc was incorporated in 2005 and is based in Oxford, the United Kingdom.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Oxford Nanopore Technologies plc, and the rating behind it. ONTTF last traded at $1.85; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Oxford Nanopore Technologies plc. Starting points for Oxford Nanopore Technologies plc: EPS -$0.16, beta 0.89 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Oxford Nanopore Technologies plc. Oxford Nanopore Technologies plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Oxford Nanopore Technologies plc. Trailing twelve-month EPS for Oxford Nanopore Technologies plc stands at -$0.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Oxford Nanopore Technologies plc. Oxford Nanopore Technologies plc has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Oxford Nanopore Technologies plc valued side by side against its closest peers. Oxford Nanopore Technologies plc is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Oxford Nanopore Technologies plc, and how their positions are changing. At a $1.79B market value, institutional positions materially move Oxford Nanopore Technologies plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Oxford Nanopore Technologies plc executives and directors. Shares of Oxford Nanopore Technologies plc have traded between $1.07 and $3.34 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Oxford Nanopore Technologies plc. Oxford Nanopore Technologies plc is a $1.79B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Oxford Nanopore Technologies plc. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Oxford Nanopore Technologies plc. Coverage tracks Oxford Nanopore Technologies plc within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • BRCTF — BioArctic AB (publ)
  • CSPHF — CStone Pharmaceuticals
  • GENSF — Genus plc
  • MEOBF — Mesoblast Limited
  • NURPF — Neuren Pharmaceuticals Limited
  • PHMMF — Pharma Mar, S.A.
  • PPTDF — PeptiDream Inc.
  • STSEY — Stratec SE

More Biotechnology companies

  • NTHI — Neonc Technologies Holdings, Inc.
  • NTI.AX — Neurotech International Limited
  • NTII — Neurobiological Technologies, Inc.
  • NTLA — Intellia Therapeutics, Inc.
  • NTRB — Nutriband Inc.
  • NTRBW — Nutriband Inc.
  • NTRR — Neutra Corp.
  • NUVB — Nuvation Bio Inc.
  • NUZ.AX — Neurizon Therapeutics Limited
  • NVAX — Novavax, Inc.
  • NVCT — Nuvectis Pharma, Inc.

News

Latest Market News